mRNA Therapeutics Market by Product (Vaccines, Drugs), Application (Oncology, Rare Diseases, Infectious Diseases, Other Applications), End User (Hospitals & Clinics, Research Settings) - Global Forecast to 2027
The global mRNA therapeutics market is projected to reach USD ~35 billion by 2027 from USD 32 billion in 2022, at a CAGR of ~2% between 2022 and 2027.
To know about the assumptions considered for the study, Request for Free Sample Report
mRNA therapeutics development involves transient expression of mRNAs that encode specific proteins or peptides in the cytoplasm. mRNAs act as the intermediates between the encoded proteins and the coding genomic DNA and are transient blueprints of genes encoded within the genomic DNA. Several treatment modalities, such as replacement therapy, vaccination, Attributed to the ease of manufacturing and development of RNA therapeutics and ability to modify the RNA sequences to design personalized RNA therapy, mRNA therapeutics is set to gain immense traction in the coming years.
Prophylactic vaccines represent a significant portion of the research & development activities pertaining to the mRNA therapeutics market. More than 70% of companies operational in this market have at least one prophylactic vaccine in their pipeline. Additionally, focus of these vaccines on COVID-19 is expected to fuel the overall market growth. Demand for prophylactic vaccines is also set to expand across different applications such as such as influenza and respiratory syncytial virus. Therapeutic vaccines is presently a nascent area of mRNA therapeutics market, the growth of which is largely hindered by manufacturing and regulatory challenges. However, expanding size of patient population and ability to target multiple tumour-associated antigens poses a significant commercial opportunity in this segment.
The mRNA therapeutics market is segmented based on product, application, end users, and region. Based on product, the market is segmented into vaccines and drugs. By application, the market is segmented into infectious diseases, rare genetic diseases, respiratory diseases, and other applications. The end users analyzed in this market include hospitals & clinics, research & other end users.
The mRNA therapeutics market includes comprehensive analysis on regions, segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Some of the major players in the global mRNA therapeutics market are Crispr Therapeutics AG, Astrazeneca PLC, Pfizer Inc., Sangamo Therapeutics, Inc., Moderna, Inc., Curevac N.V., Arcturus Therapeutics, Translate Bio, Inc., GSK PLC., and Argos Therapeutics Inc.
To know about the assumptions considered for the study, download the pdf brochure
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
This report categorizes the mRNA Therapeutics market into the following segments:
mRNA Therapeutics Market, By Product
- Vaccines
- Drugs
mRNA Therapeutics Market, By Application
- Infectious Diseases
- Rare Genetic Diseases
- Respiratory Diseases
- Other Applications
mRNA Therapeutics Market, By End User
- Hospitals & Clinics
- Research & Other End Users
mRNA Therapeutics Market, By Region
- North America
- US
- Canada
- Europe
- Germany
- France
- Uk
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Rest Of Asia Pacific
- Rest Of The World (ROW)
- Latin America
- Middle East And Africa
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKET COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.1.2.1 KEY INDUSTRY INSIGHTS
2.2 MARKET SIZE ESTIMATION
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.3 TECHNOLOGY ANALYSIS
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.5 PRICING ANALYSIS
5.6 VALUE/SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 PATENT ANALYSIS
5.9 KEY CONFERENCES AND EVENTS IN 2022-2023
5.10 REGULATORY ANALYSIS
5.11 PORTER’S FIVE FORCES ANALYSIS
5.12 KEY STAKEHOLDER AND BUYING CRITERIA
6 MRNA THERAPEUTICS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
6.1 INTRODUCTION
6.2 VACCINES
6.3 DRUGS
7 MRNA THERAPEUTICS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
7.1 ONCOLOGY
7.2 INFECTIOUS DISEASES
7.3 RARE GENETIC DISEASES
7.4 RESPIRATORY DISEASES
7.5 OTHER APPLICATIONS
8 MRNA THERAPEUTICS MARKET, BY END USER, 2020-2027 (USD MILLION)
8.1 INTRODUCTION
8.2 HOSPITALS & CLINICS
8.3 RESEARCH & OTHER END USERS
9 MRNA THERAPEUTICS MARKET, BY REGION, 2020-2027 (USD MILLION)
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 US
9.2.2 CANADA
9.3 EUROPE
9.3.1 GERMANY
9.3.2 FRANCE
9.3.3 UK
9.3.4 ROE
9.4 ASIA PACIFIC
9.4.1 JAPAN
9.4.2 CHINA
9.4.3 INDIA
9.4.4 REST OF APAC
9.5 REST OF THE WORLD (ROW)
9.5.1 LATIN AMERICA
9.5.2 MIDDLE EAST & AFRICA
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES
10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
10.4 MARKET SHARE/RANKING ANALYSIS, 2021
10.5 COMPANY EVALUATION QUADRANT
10.6 COMPANY EVALUATION QUADRANT – SME/START-UPS
10.7 COMPANY GEOGRAPHIC FOOTPRINT
10.8 COMPETITIVE SCENARIO
11 COMPANY PROFILES
(The details on business overview, financial information, products/services portfolio, recent developments, MarketsandMarkets view will be provided)*
11.1 CRISPR THERAPEUTICS AG
11.2 ASTRAZENECA PLC.
11.3 PFIZER INC.
11.4 SANGAMO THERAPEUTICS, INC.
11.5 MODERNA, INC.
11.6 CUREVAC N.V.
11.7 ARCTURUS THERAPEUTICS
11.8 TRANSLATE BIO, INC.
11.9 GSK PLC.
11.10 ARGOS THERAPEUTICS INC.
* Details on business overview, financial information, products/services portfolio, recent developments, MarketsandMarkets view might not be captured in case of unlisted companies.
12 APPENDIX
12.1 INSIGHTS FROM INDUSTRY EXPERTS
12.2 DISCUSSION GUIDE
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
12.5 AVAILABLE CUSTOMIZATIONS
12.6 RELATED REPORTS
12.7 AUTHOR DETAILS
Growth opportunities and latent adjacency in mRNA Therapeutics Market